People · Operator
Named in public records as an officer, director or promoter · active 2018–2024 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tharimmune, Inc. | — | Biotechnology | Seed | $6.6M | $7.2M | 2024 |
| Khloris Biosciences, Inc. | — | Pharmaceuticals | Series A | $5.0M | $154.9M | 2018 |
Lynne A/ Bui at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lynne A/ Bui on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Leonard Mazur | 1 | 3 |
| Clay Kahler | 1 | 1 |
| James Gordon Liddy | 1 | 1 |
| Sireesh Appajosyula | 1 | 1 |
| Gary Stetz | 1 | 1 |
| Sanam Parikh | 1 | 1 |
| Vincent LoPriore | 1 | 1 |
| Thomas Hess | 1 | 1 |
| Sanam A/ Parikh | 1 | 1 |
| Kelly A/ Anderson | 1 | 1 |
| Randy Milby | 1 | 1 |
| Joseph C. Wu | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.